US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
US7544511B2
(en)
*
|
1996-09-25 |
2009-06-09 |
Neuralstem Biopharmaceuticals Ltd. |
Stable neural stem cell line methods
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
CZ20012358A3
(cs)
*
|
1998-12-31 |
2002-01-16 |
Societe De Conseils De Recherches Et D´Application |
Prenyltransferázové inhibitory
|
ES2257555T3
(es)
|
2001-06-20 |
2006-08-01 |
MERCK & CO., INC. |
Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
|
DE60224189T2
(de)
|
2001-06-20 |
2008-12-11 |
Merck & Co., Inc. |
Dipeptidylpeptidase-hemmer zur behandlung von diabetes
|
ES2339813T3
(es)
|
2001-06-27 |
2010-05-25 |
Glaxosmithkline Llc |
Fluoropirrolidinas como inhibidores de dipeptidil peptidasas.
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
CA2472956A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Formulation strategies in stabilizing peptides in organic solvents and in dried states
|
EP1490335B1
(en)
*
|
2002-03-25 |
2007-09-19 |
Merck & Co., Inc. |
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US7208498B2
(en)
*
|
2002-07-15 |
2007-04-24 |
Merck & Co., Inc. |
Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
DE60315687T2
(de)
*
|
2002-10-07 |
2008-06-05 |
Merck & Co., Inc. |
Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
|
ATE390416T1
(de)
*
|
2002-10-18 |
2008-04-15 |
Merck & Co Inc |
Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
|
BR0315796A
(pt)
|
2002-11-07 |
2005-09-13 |
Merck & Co Inc |
Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
|
EP1578414A4
(en)
*
|
2002-12-04 |
2007-10-24 |
Merck & Co Inc |
PHENYLALANINE DERIVATIVES ALSDIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
US8293488B2
(en)
|
2002-12-09 |
2012-10-23 |
Neuralstem, Inc. |
Method for screening neurogenic agents
|
WO2004053071A2
(en)
*
|
2002-12-09 |
2004-06-24 |
Judith Kelleher-Andersson |
Method for discovering neurogenic agents
|
WO2004052362A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Novartis Ag |
Combination of an dpp-iv inhibitor and a ppar-alpha compound
|
EP1583534A4
(en)
*
|
2002-12-20 |
2007-08-29 |
Merck & Co Inc |
3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
ATE374766T1
(de)
|
2003-01-14 |
2007-10-15 |
Arena Pharm Inc |
1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
|
JP4564952B2
(ja)
*
|
2003-01-17 |
2010-10-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP2006516573A
(ja)
*
|
2003-01-31 |
2006-07-06 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
|
AR043443A1
(es)
*
|
2003-03-07 |
2005-07-27 |
Merck & Co Inc |
Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
|
AR043505A1
(es)
*
|
2003-03-18 |
2005-08-03 |
Merck & Co Inc |
Preparacion de beta-cetoamidas e intermediarios de reaccion
|
AR043515A1
(es)
*
|
2003-03-19 |
2005-08-03 |
Merck & Co Inc |
Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
|
WO2004085661A2
(en)
*
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc |
Process to chiral beta-amino acid derivatives
|
WO2004087053A2
(en)
|
2003-03-25 |
2004-10-14 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2004087650A2
(en)
*
|
2003-03-27 |
2004-10-14 |
Merck & Co. Inc. |
Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
|
DE602004026289D1
(de)
|
2003-05-05 |
2010-05-12 |
Probiodrug Ag |
Glutaminylcyclase-hemmer
|
GB0310593D0
(en)
*
|
2003-05-08 |
2003-06-11 |
Leuven K U Res & Dev |
Peptidic prodrugs
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
ATE447574T1
(de)
*
|
2003-05-14 |
2009-11-15 |
Merck & Co Inc |
3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
|
WO2004110375A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes
|
CA2526770A1
(en)
*
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
CN1809544A
(zh)
*
|
2003-06-17 |
2006-07-26 |
麦克公司 |
作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物
|
JO2625B1
(en)
*
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
AU2004257267B2
(en)
|
2003-07-14 |
2009-12-03 |
Arena Pharmaceuticals,Inc |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
WO2005012346A1
(en)
*
|
2003-07-25 |
2005-02-10 |
Conjuchem, Inc. |
Long lasting insulin derivatives and methods thereof
|
EP1651623B1
(en)
*
|
2003-07-31 |
2008-12-17 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1506967B1
(en)
*
|
2003-08-13 |
2007-11-21 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN100457108C
(zh)
*
|
2003-09-02 |
2009-02-04 |
默克公司 |
一种二肽基肽酶iv抑制剂的磷酸盐新晶体
|
US20050065144A1
(en)
*
|
2003-09-08 |
2005-03-24 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
EP1699777B1
(en)
*
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN1902177A
(zh)
|
2003-09-22 |
2007-01-24 |
万有制药株式会社 |
新哌啶衍生物
|
US20070021430A1
(en)
*
|
2003-09-23 |
2007-01-25 |
Chen Alex M |
Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
|
EP1684786A4
(en)
*
|
2003-10-24 |
2007-12-12 |
Merck & Co Inc |
IMPROVING THE HORMONAL LEVEL OF GROWTH
|
ZA200603165B
(en)
|
2003-11-03 |
2007-07-25 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
US7238683B2
(en)
*
|
2003-11-04 |
2007-07-03 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
CA2545311C
(en)
*
|
2003-11-12 |
2012-01-03 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20120008093A
(ko)
|
2003-11-17 |
2012-01-25 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
WO2005072530A1
(en)
*
|
2004-01-16 |
2005-08-11 |
Merck & Co., Inc. |
Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
|
LT3366283T
(lt)
|
2004-01-20 |
2021-12-10 |
Novartis Ag |
Tiesioginio presavimo formulė ir procesas
|
SI1712547T1
(sl)
*
|
2004-02-05 |
2012-04-30 |
Kyorin Seiyaku Kk |
Bicikloestrski derivat
|
CN1918131B
(zh)
|
2004-02-05 |
2011-05-04 |
前体生物药物股份公司 |
谷氨酰胺酰基环化酶抑制剂
|
EP1717225A4
(en)
*
|
2004-02-18 |
2009-10-21 |
Kyorin Seiyaku Kk |
BICYCLIC AMIDE DERIVATIVES
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005082847A1
(ja)
*
|
2004-02-27 |
2005-09-09 |
Kyorin Pharmaceutical Co., Ltd. |
ビシクロ誘導体
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
GEP20094679B
(en)
*
|
2004-03-15 |
2009-05-10 |
Takeda Pharmaceuticals Co |
Dipeptidyl peptidase inhibitors
|
US20080255216A1
(en)
|
2004-03-29 |
2008-10-16 |
Aster Susan D |
Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
|
WO2005097127A2
(en)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Method of treating men with metabolic and anthropometric disorders
|
TW200602293A
(en)
*
|
2004-04-05 |
2006-01-16 |
Merck & Co Inc |
Process for the preparation of enantiomerically enriched beta amino acid derivatives
|
US7687492B2
(en)
*
|
2004-05-04 |
2010-03-30 |
Merck Sharp & Dohme Corp. |
1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
EP1756106A4
(en)
*
|
2004-05-18 |
2008-12-17 |
Merck & Co Inc |
CYCLOHEXYLALANINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
|
JP2008501714A
(ja)
|
2004-06-04 |
2008-01-24 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼインヒビター
|
CA2570807C
(en)
*
|
2004-06-21 |
2011-12-06 |
Merck & Co., Inc. |
Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
JP2008507541A
(ja)
*
|
2004-07-23 |
2008-03-13 |
ロイヤルティ,スーザン・マリー |
ペプチダーゼ阻害剤
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
EP1797034B1
(en)
|
2004-08-06 |
2010-06-30 |
Merck Sharp & Dohme Corp. |
Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
US7625888B2
(en)
|
2004-08-23 |
2009-12-01 |
Merck & Co., Inc. |
Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
WO2006022428A1
(ja)
*
|
2004-08-26 |
2006-03-02 |
Takeda Pharmaceutical Company Limited |
糖尿病治療剤
|
PE20060652A1
(es)
|
2004-08-27 |
2006-08-11 |
Novartis Ag |
Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
|
WO2006033848A1
(en)
*
|
2004-09-15 |
2006-03-30 |
Merck & Co., Inc. |
Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
CA2582447C
(en)
|
2004-10-01 |
2012-04-17 |
Merck & Co., Inc. |
Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
AP2007003973A0
(en)
*
|
2004-10-12 |
2007-07-30 |
Glenmark Pharmaceuticals Sa |
Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
ES2537004T3
(es)
*
|
2004-11-17 |
2015-06-01 |
Neuralstem, Inc. |
Trasplante de células neurales humanas para el tratamiento de afecciones neurodegenerativas
|
JP2008524331A
(ja)
*
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
EA015382B1
(ru)
*
|
2005-03-08 |
2011-08-30 |
Никомед Гмбх |
Применение рофлумиласта для лечения сахарного диабета типа 2
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
CA2606188A1
(en)
*
|
2005-05-02 |
2006-11-09 |
Merck & Co., Inc. |
Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
|
JP5069678B2
(ja)
*
|
2005-05-25 |
2012-11-07 |
メルク・シャープ・エンド・ドーム・コーポレイション |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼiv阻害剤としてのアミノシクロヘキサン
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
BRPI0610580B8
(pt)
|
2005-05-30 |
2021-05-25 |
Banyu Pharma Co Ltd |
composto derivado de piperidina
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
JP4915833B2
(ja)
*
|
2005-07-01 |
2012-04-11 |
雪印メグミルク株式会社 |
ジペプチジルペプチダーゼiv阻害剤
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
DE602006007012D1
(de)
*
|
2005-07-20 |
2009-07-09 |
Lilly Co Eli |
Pyridinderivate als dipeptedyl-peptidase-hemmer
|
WO2007015807A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
Phenyl compounds
|
EP1909776A2
(en)
*
|
2005-07-25 |
2008-04-16 |
Merck & Co., Inc. |
Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
AU2006277253A1
(en)
|
2005-08-10 |
2007-02-15 |
Msd K.K. |
Pyridone compound
|
AU2006282260A1
(en)
|
2005-08-24 |
2007-03-01 |
Msd K.K. |
Phenylpyridone derivative
|
US7709468B2
(en)
|
2005-09-02 |
2010-05-04 |
Abbott Laboratories |
Imidazo based heterocycles
|
JPWO2007029847A1
(ja)
|
2005-09-07 |
2009-03-19 |
萬有製薬株式会社 |
二環性芳香族置換ピリドン誘導体
|
CA2622608C
(en)
*
|
2005-09-14 |
2014-08-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
EP2073810B1
(en)
*
|
2006-09-13 |
2011-08-31 |
Takeda Pharmaceutical Company Limited |
Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
|
MY147393A
(en)
|
2005-09-14 |
2012-11-30 |
Takeda Pharmaceutical |
Administration of dipeptidyl peptidase inhibitors
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
CN102675221A
(zh)
*
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JP2009513633A
(ja)
*
|
2005-10-25 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−4インヒビターと降圧薬との組合せ
|
WO2007049798A1
(ja)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
新規ベンゾオキサチイン誘導体
|
NZ568292A
(en)
|
2005-11-10 |
2011-08-26 |
Msd Kk |
Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
|
WO2007078726A2
(en)
*
|
2005-12-16 |
2007-07-12 |
Merck & Co., Inc. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
GB0526291D0
(en)
*
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
JP5094416B2
(ja)
*
|
2005-12-28 |
2012-12-12 |
武田薬品工業株式会社 |
糖尿病治療剤
|
US20090156465A1
(en)
|
2005-12-30 |
2009-06-18 |
Sattigeri Jitendra A |
Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
|
KR20080089461A
(ko)
*
|
2005-12-30 |
2008-10-06 |
랜박시 래보러터리스 리미티드 |
무스카린 수용체 길항제
|
US7750034B2
(en)
*
|
2006-01-25 |
2010-07-06 |
Merck Sharp & Dohme Corp. |
Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
AU2007224066B2
(en)
*
|
2006-03-08 |
2011-10-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1999108A1
(en)
*
|
2006-03-28 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
MEP27308A
(en)
|
2006-04-11 |
2010-06-10 |
Arena Pharm Inc |
Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
|
BRPI0709961A2
(pt)
|
2006-04-11 |
2011-08-02 |
Novartis Ag |
compostos orgánicos
|
PE20110235A1
(es)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
US20100179131A1
(en)
|
2006-09-07 |
2010-07-15 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
JPWO2008038692A1
(ja)
|
2006-09-28 |
2010-01-28 |
萬有製薬株式会社 |
ジアリールケチミン誘導体
|
JP5379692B2
(ja)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
ATE554085T1
(de)
|
2006-11-30 |
2012-05-15 |
Probiodrug Ag |
Neue inhibitoren von glutaminylcyclase
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
KR20080071476A
(ko)
*
|
2007-01-30 |
2008-08-04 |
주식회사 엘지생명과학 |
신규한 디펩티딜 펩티데이즈 iv(dpp-iv) 저해제
|
JP5284968B2
(ja)
*
|
2007-02-01 |
2013-09-11 |
武田薬品工業株式会社 |
アログリプチンおよびピオグリタゾンを含有する固形製剤
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
JPWO2008114857A1
(ja)
*
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
AU2008233548B2
(en)
|
2007-04-03 |
2011-12-01 |
Mitsubishi Tanabe Pharma Corporation |
Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
|
DK2142514T3
(da)
|
2007-04-18 |
2015-03-23 |
Probiodrug Ag |
Thioureaderivater som glutaminylcyclase-inhibitorer
|
EP2155187B1
(en)
|
2007-05-07 |
2016-05-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
WO2008141021A1
(en)
*
|
2007-05-08 |
2008-11-20 |
Concert Pharmaceuticals, Inc. |
Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
|
CN101742906A
(zh)
|
2007-06-04 |
2010-06-16 |
本古里安大学内盖夫研究发展局 |
三芳基化合物和包含它们的组合物
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EA020466B1
(ru)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
|
CN101318922B
(zh)
*
|
2007-06-08 |
2010-11-10 |
上海阳帆医药科技有限公司 |
一类二肽基肽酶抑制剂、合成方法和用途
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
CN101784278A
(zh)
*
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
CN101397300B
(zh)
*
|
2007-09-04 |
2011-04-27 |
山东轩竹医药科技有限公司 |
二肽酶-ⅳ抑制剂衍生物
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
CN101417999A
(zh)
*
|
2007-10-25 |
2009-04-29 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
WO2009084024A2
(en)
*
|
2007-11-02 |
2009-07-09 |
Glenmark Generics Limited |
A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
|
US20090192326A1
(en)
*
|
2007-11-13 |
2009-07-30 |
Nurit Perlman |
Preparation of sitagliptin intermediate
|
CA2707790C
(en)
|
2007-12-20 |
2015-04-21 |
Dr. Reddy's Laboratories Limited |
Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
|
AU2008341352B2
(en)
*
|
2007-12-21 |
2013-08-01 |
Lg Chem, Ltd. |
Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
|
CN101468988A
(zh)
*
|
2007-12-26 |
2009-07-01 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
EP2250157B1
(en)
*
|
2008-01-24 |
2014-11-05 |
Panacea Biotec Limited |
Novel heterocyclic compounds
|
WO2009099734A1
(en)
*
|
2008-02-05 |
2009-08-13 |
Merck & Co., Inc. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
EP2259676A4
(en)
*
|
2008-03-04 |
2011-03-16 |
Merck Sharp & Dohme |
PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
|
AU2009220605A1
(en)
|
2008-03-06 |
2009-09-11 |
Msd K.K. |
Alkylaminopyridine derivative
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
US20090247532A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Mae De Ltd. |
Crystalline polymorph of sitagliptin phosphate and its preparation
|
AU2009229860A1
(en)
|
2008-03-28 |
2009-10-01 |
Msd K.K. |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
US20090264476A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Mckelvey Craig |
CB-1 receptor modulator formulations
|
US8003672B2
(en)
*
|
2008-04-21 |
2011-08-23 |
Merck Sharp & Dohme Corp. |
CB-1 receptor modulator formulations
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20110071129A1
(en)
|
2008-06-19 |
2011-03-24 |
Makoto Ando |
Spirodiamine-diaryl ketoxime derivative
|
PT2586782E
(pt)
|
2008-07-03 |
2015-02-03 |
Ratiopharm Gmbh |
Sais cristalinos de sitagliptina
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
EP2324027B1
(en)
*
|
2008-07-29 |
2016-02-24 |
Medichem, S.A. |
New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
|
JPWO2010013595A1
(ja)
|
2008-07-30 |
2012-01-12 |
Msd株式会社 |
5員−5員又は5員−6員縮環シクロアルキルアミン誘導体
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
US8476470B2
(en)
*
|
2008-08-07 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Process for production of bicyclo[2.2.2]octylamine derivative
|
CN102186474A
(zh)
*
|
2008-08-14 |
2011-09-14 |
杏林制药株式会社 |
稳定的医药组合物
|
MX370599B
(es)
|
2008-08-15 |
2019-12-18 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
WO2010032264A2
(en)
*
|
2008-08-27 |
2010-03-25 |
Cadila Healthcare Limited |
Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US8361959B2
(en)
|
2008-10-03 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Spiro-imidazolone derivatives as glucagon receptor antagonists
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
KR101054911B1
(ko)
*
|
2008-10-17 |
2011-08-05 |
동아제약주식회사 |
디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
PE20110852A1
(es)
|
2008-10-30 |
2011-11-25 |
Merck Sharp & Dohme |
Antagonistas del receptor de orexina de isonicotinamida
|
CA2741672A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
EP2358200A4
(en)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
ES2603215T3
(es)
*
|
2008-12-31 |
2017-02-24 |
Chiral Quest, Inc. |
Procedimiento y productos intermedios para la preparación de derivados de beta-aminoácidos N-acilados-4-arilo
|
US8404727B2
(en)
*
|
2009-01-07 |
2013-03-26 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CN102272099A
(zh)
|
2009-01-09 |
2011-12-07 |
幽兰研究实验室有限公司 |
二肽基肽酶iv抑制剂
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
EP2218721A1
(en)
|
2009-02-11 |
2010-08-18 |
LEK Pharmaceuticals d.d. |
Novel salts of sitagliptin
|
SG173619A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
WO2010092163A2
(en)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications
|
EP2223923A1
(en)
|
2009-02-25 |
2010-09-01 |
Esteve Química, S.A. |
Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof
|
CN101824036A
(zh)
*
|
2009-03-05 |
2010-09-08 |
上海恒瑞医药有限公司 |
四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
|
MX2011010204A
(es)
|
2009-03-30 |
2011-10-17 |
Dong A Pharm Co Ltd |
Procedimiento mejorado para preparar inhibidor de dipeptidil peptidasa-iv e intermediario.
|
US8598347B2
(en)
|
2009-03-30 |
2013-12-03 |
Dong-A Pharmaceutical. Co., Ltd |
Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate
|
CN101849944A
(zh)
*
|
2009-03-31 |
2010-10-06 |
江苏恒瑞医药股份有限公司 |
治疗2型糖尿病的药物组合物
|
WO2010122578A2
(en)
*
|
2009-04-20 |
2010-10-28 |
Msn Laboratories Limited |
Process for the preparation of sitagliptin and its intermediates
|
WO2010131025A1
(en)
*
|
2009-05-11 |
2010-11-18 |
Generics [Uk] Limited |
Sitagliptin synthesis
|
CN101899047B
(zh)
*
|
2009-05-26 |
2016-01-20 |
盛世泰科生物医药技术(苏州)有限公司 |
作为二肽基肽酶抑制剂用于治疗或预防糖尿病的β-氨基四氢吡嗪、四氢嘧啶和四氢吡啶
|
CN101899048B
(zh)
|
2009-05-27 |
2013-04-17 |
上海恒瑞医药有限公司 |
(R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
|
EP2440553B1
(en)
|
2009-06-12 |
2017-08-23 |
Merck Sharp & Dohme Corp. |
Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
|
IT1395596B1
(it)
*
|
2009-06-30 |
2012-10-16 |
Dipharma Francis Srl |
Procedimento per la preparazione di sitagliptin
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
AR077463A1
(es)
*
|
2009-07-09 |
2011-08-31 |
Irm Llc |
Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011016220A1
(ja)
|
2009-08-03 |
2011-02-10 |
株式会社カネカ |
ジペプチジルペプチダーゼ-4阻害剤
|
WO2011019538A1
(en)
|
2009-08-13 |
2011-02-17 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
AU2010283689B2
(en)
|
2009-08-13 |
2016-07-14 |
Sandoz Ag |
Crystalline compound of 7-[(3R)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazine
|
EP2473047B1
(en)
|
2009-09-02 |
2014-08-13 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US8486940B2
(en)
|
2009-09-11 |
2013-07-16 |
Probiodrug Ag |
Inhibitors
|
EP2295083A1
(de)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
|
CN102030683B
(zh)
*
|
2009-09-27 |
2013-07-31 |
浙江九洲药业股份有限公司 |
西他列汀中间体及其制备方法和用途
|
EP2308847B1
(en)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
|
CA2779088A1
(en)
|
2009-11-16 |
2011-05-19 |
Mellitech |
[1,5]-diazocin derivatives
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
KR101156587B1
(ko)
|
2010-02-19 |
2012-06-20 |
한미사이언스 주식회사 |
시타글립틴의 제조방법 및 이에 사용되는 아민염 중간체
|
EP2538783B1
(en)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EP2542549B1
(en)
|
2010-03-03 |
2016-05-11 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
BR112012022478B1
(pt)
|
2010-03-10 |
2021-09-21 |
Probiodrug Ag |
Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
|
CZ303113B6
(cs)
|
2010-03-16 |
2012-04-11 |
Zentiva, K.S. |
Zpusob prípravy sitagliptinu
|
EP2547339A1
(en)
|
2010-03-18 |
2013-01-23 |
Boehringer Ingelheim International GmbH |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
KR20120139764A
(ko)
|
2010-03-31 |
2012-12-27 |
테바 파마슈티컬 인더스트리즈 리미티드 |
시타글립틴염의 고체 형태
|
WO2011125011A1
(en)
*
|
2010-04-05 |
2011-10-13 |
Cadila Pharmaceuticals Limited |
Novel hypoglycemic compounds
|
EP2556056A1
(en)
|
2010-04-06 |
2013-02-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
CA2796327A1
(en)
|
2010-04-28 |
2011-11-03 |
Sun Pharmaceutical Industries Ltd. |
Process for the preparation of chiral beta-amino carboxamide derivatives
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
CN103038236B
(zh)
*
|
2010-06-04 |
2015-09-30 |
力奇制药公司 |
β-氨基丁酰基取代的化合物的新合成方法
|
EP2392575A1
(en)
|
2010-06-04 |
2011-12-07 |
LEK Pharmaceuticals d.d. |
A novel synthetic approach to ß-aminobutyryl substituted compounds
|
EP2397141A1
(en)
|
2010-06-16 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
Process for the synthesis of beta-amino acids and derivatives thereof
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
EP2407469A1
(en)
|
2010-07-13 |
2012-01-18 |
Chemo Ibérica, S.A. |
Salt of sitagliptin
|
US9540611B2
(en)
|
2010-07-28 |
2017-01-10 |
Neuralstem, Inc. |
Methods for treating and/or reversing neurodegenerative diseases and/or disorders
|
EP2423178A1
(en)
|
2010-07-28 |
2012-02-29 |
Chemo Ibérica, S.A. |
Process for the production of sitagliptin
|
EP2418196A1
(en)
*
|
2010-07-29 |
2012-02-15 |
IMTM GmbH |
Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
|
EP2605658B1
(en)
|
2010-08-18 |
2016-03-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
EP2609099A2
(en)
|
2010-08-27 |
2013-07-03 |
USV Limited |
Sitagliptin, salts and polymorphs thereof
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
WO2012035549A2
(en)
|
2010-09-13 |
2012-03-22 |
Panacea Biotec Ltd |
An improved process for the synthesis of beta amino acid derivatives
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CA2812061A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2625179A2
(en)
*
|
2010-10-08 |
2013-08-14 |
Cadila Healthcare Limited |
Process for preparing an intermediate of sitagliptin via enzymatic conversion
|
WO2012049566A1
(en)
|
2010-10-14 |
2012-04-19 |
Japan Tobacco Inc. |
Combination therapy for use in treating diabetes
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102485718B
(zh)
|
2010-12-03 |
2014-03-26 |
浙江海翔药业股份有限公司 |
西他列汀的中间体及其制备方法
|
WO2012078448A1
(en)
|
2010-12-06 |
2012-06-14 |
Schering Corporation |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
WO2012076973A2
(en)
|
2010-12-09 |
2012-06-14 |
Aurobindo Pharma Limited |
Novel salts of dipeptidyl peptidase iv inhibitor
|
TWI494313B
(zh)
*
|
2010-12-29 |
2015-08-01 |
Jiangsu Hengrui Medicine Co |
治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
ES2834986T3
(es)
|
2011-01-07 |
2021-06-21 |
Anji Pharma Us Llc |
Terapias basadas en ligandos de receptores quimiosensoriales
|
US11974971B2
(en)
|
2011-01-07 |
2024-05-07 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
KR101290029B1
(ko)
*
|
2011-01-20 |
2013-07-30 |
에스티팜 주식회사 |
시타글립틴의 중간체 제조방법
|
WO2012104869A1
(en)
|
2011-01-31 |
2012-08-09 |
Cadila Healthcare Limited |
Treatment for lipodystrophy
|
EP3243385B1
(en)
|
2011-02-25 |
2021-01-13 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
EA201391254A1
(ru)
|
2011-03-01 |
2014-02-28 |
Синерджи Фармасьютикалз Инк. |
Способ получения агонистов гуанилатциклазы c
|
SG192973A1
(en)
*
|
2011-03-03 |
2013-09-30 |
Cadila Healthcare Ltd |
Novel salts of dpp-iv inhibitor
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
EP2691083B1
(en)
|
2011-03-29 |
2017-08-02 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition of sitagliptin
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CA2831334A1
(en)
|
2011-04-08 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2508506A1
(en)
|
2011-04-08 |
2012-10-10 |
LEK Pharmaceuticals d.d. |
Preparation of sitagliptin intermediates
|
KR101369584B1
(ko)
|
2011-04-19 |
2014-03-06 |
일양약품주식회사 |
페닐-이속사졸 유도체 및 그의 제조방법
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
CN102757431B
(zh)
*
|
2011-04-24 |
2016-03-30 |
浙江华海药业股份有限公司 |
一种合成西他列汀的新方法
|
ITMI20110765A1
(it)
|
2011-05-05 |
2012-11-06 |
Chemo Iberica Sa |
Processo per la produzione di sitagliptina
|
US8524936B2
(en)
|
2011-05-18 |
2013-09-03 |
Milan Soukup |
Manufacturing process for sitagliptin from L-aspartic acid
|
US9359385B2
(en)
*
|
2011-05-27 |
2016-06-07 |
Lek Pharmaceuticals D.D. |
Preparation of sitagliptin intermediates
|
EP2527320A1
(en)
|
2011-05-27 |
2012-11-28 |
LEK Pharmaceuticals d.d. |
Preparation of Sitagliptin Intermediates
|
US20140088124A1
(en)
|
2011-06-02 |
2014-03-27 |
Robert J. DeVita |
Imidazole derivatives
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
AR086675A1
(es)
*
|
2011-06-14 |
2014-01-15 |
Merck Sharp & Dohme |
Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
|
WO2012173917A1
(en)
|
2011-06-16 |
2012-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
CA2838738A1
(en)
|
2011-06-29 |
2013-01-03 |
Merck Sharp & Dohme Corp. |
Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
|
EP2726484A1
(en)
|
2011-06-29 |
2014-05-07 |
Ranbaxy Laboratories Limited |
Solid dispersions of sitagliptin and processes for their preparation
|
AU2012277403A1
(en)
|
2011-06-30 |
2014-01-30 |
Ranbaxy Laboratories Limited |
Novel salts of sitagliptin
|
US9051329B2
(en)
|
2011-07-05 |
2015-06-09 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
EP2736909B1
(en)
|
2011-07-27 |
2017-03-29 |
Farma GRS, d.o.o. |
Process for the preparation of sitagliptin and its pharmaceutically acceptable salts
|
EA201490556A1
(ru)
|
2011-09-07 |
2014-08-29 |
Сановел Илач Санайи Ве Тиджарет Аноним Ширкети |
Составы ингибитора дпп-4
|
EP2760855B1
(en)
|
2011-09-30 |
2017-03-15 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
|
ES2487271T3
(es)
|
2011-10-06 |
2014-08-20 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulaciones de dosificación sólidas inhibidoras de DPP-IV
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CN106905321A
(zh)
|
2011-10-14 |
2017-06-30 |
劳乐斯实验室私营有限公司 |
新的西他列汀盐、其制备方法及其药物组合物
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
WO2013062838A1
(en)
|
2011-10-24 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as gpr119 agonists
|
CN102603749B
(zh)
*
|
2011-10-27 |
2017-02-08 |
浙江华海药业股份有限公司 |
一种西他列汀中间体的合成方法
|
WO2013065066A1
(en)
|
2011-11-02 |
2013-05-10 |
Cadila Healthcare Limited |
Processes for preparing 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,41-triazolo[43-a]pyrazin-7(8h)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
US9018224B2
(en)
|
2011-11-15 |
2015-04-28 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as GPR119 agonists
|
US20140350023A1
(en)
|
2011-12-08 |
2014-11-27 |
Ranbaxy Laboratories Limited |
Amorphous form of sitagliptin salts
|
KR102231554B1
(ko)
|
2012-01-06 |
2021-03-23 |
앤지 파마 유에스 엘엘씨 |
대사 장애를 치료하는 조성물 및 방법
|
BR112014016808B1
(pt)
|
2012-01-06 |
2022-01-11 |
Anji Pharma (Us) Llc |
Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
|
EP2615080A1
(en)
|
2012-01-12 |
2013-07-17 |
LEK Pharmaceuticals d.d. |
Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
|
EP2814485A4
(en)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
ES2421956B1
(es)
|
2012-03-02 |
2014-09-29 |
Moehs Ibérica S.L. |
Nueva forma cristalina de sulfato de sitagliptina
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
CN104411710A
(zh)
|
2012-04-16 |
2015-03-11 |
卡内克制药公司 |
作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
|
TWI469785B
(zh)
|
2012-04-25 |
2015-01-21 |
Inovobiologic Inc |
用於治療代謝性疾病之膳食纖維組成物
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2674432A1
(en)
|
2012-06-14 |
2013-12-18 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds
|
WO2014018355A1
(en)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-iv inhibitors
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
JP2015525782A
(ja)
|
2012-08-02 |
2015-09-07 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病性三環式化合物
|
KR20150056541A
(ko)
|
2012-08-08 |
2015-05-26 |
시플라 리미티드 |
시타글립틴 및 중간체 화합물의 제조 방법
|
CN102898387B
(zh)
*
|
2012-09-26 |
2015-01-07 |
浙江工业大学 |
管道化连续生产n-[(2z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼的方法
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
CN103788070B
(zh)
*
|
2012-10-26 |
2017-10-20 |
南京华威医药科技开发有限公司 |
Dpp‑4抑制剂类多聚物
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
CZ306115B6
(cs)
|
2012-12-04 |
2016-08-10 |
Zentiva, K.S. |
Způsob přípravy derivátů kyseliny 3-amino-4-(2,4,5-trifluorfenyl)-butanové
|
CN103319487B
(zh)
*
|
2013-01-10 |
2015-04-01 |
药源药物化学(上海)有限公司 |
西格列汀的制备方法及其中间体
|
EP2769712A1
(en)
|
2013-02-21 |
2014-08-27 |
Siegfried International AG |
Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
|
CN104994848A
(zh)
|
2013-02-22 |
2015-10-21 |
默沙东公司 |
抗糖尿病二环化合物
|
CN105669682B
(zh)
*
|
2013-02-22 |
2019-08-30 |
成都先导药物开发股份有限公司 |
一种dpp-iv抑制剂的中间体
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
IN2013MU00916A
(US08124317-20120228-C00026.png)
|
2013-03-20 |
2015-06-26 |
Cadila Healthcare Ltd |
|
KR101617812B1
(ko)
|
2013-04-22 |
2016-05-03 |
카딜라 핼쓰캐어 리미티드 |
비알콜성 지방간 질환을 위한 신규 조성물
|
US20160107989A1
(en)
|
2013-05-30 |
2016-04-21 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
PT3004138T
(pt)
|
2013-06-05 |
2024-06-18 |
Bausch Health Ireland Ltd |
Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
|
WO2015001568A2
(en)
*
|
2013-07-01 |
2015-01-08 |
Laurus Labs Private Limited |
Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
IN2013MU02470A
(US08124317-20120228-C00026.png)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
US10112898B2
(en)
|
2013-09-06 |
2018-10-30 |
Cadila Healthcare Limited |
Process for the preparation of saroglitazar pharmaceutical salts
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CZ2013842A3
(cs)
|
2013-11-01 |
2015-05-13 |
Zentiva, K.S. |
Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
CN103626775B
(zh)
*
|
2013-12-02 |
2015-05-20 |
南京华威医药科技开发有限公司 |
具有二嗪结构的dpp-4抑制剂
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
IN2014MU00212A
(US08124317-20120228-C00026.png)
|
2014-01-21 |
2015-08-28 |
Cadila Healthcare Ltd |
|
WO2015112465A1
(en)
|
2014-01-24 |
2015-07-30 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as mgat2 inhibitors
|
IN2014MU00651A
(US08124317-20120228-C00026.png)
|
2014-02-25 |
2015-10-23 |
Cadila Healthcare Ltd |
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
WO2015145333A1
(en)
|
2014-03-26 |
2015-10-01 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of sitagliptin and its intermediate
|
JP6523328B2
(ja)
|
2014-04-17 |
2019-05-29 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
タンニン酸シタグリプチン複合体
|
WO2015162506A1
(en)
|
2014-04-21 |
2015-10-29 |
Suven Life Sciences Limited |
Process for the preparation of sitagliptin and novel intermediates
|
WO2015170340A2
(en)
*
|
2014-05-06 |
2015-11-12 |
Laurus Labs Private Limited |
Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2016014324A1
(en)
|
2014-07-21 |
2016-01-28 |
Merck Sharp & Dohme Corp. |
Process for preparing chiral dipeptidyl peptidase-iv inhibitors
|
WO2016022448A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
CN104140430B
(zh)
*
|
2014-08-08 |
2016-07-13 |
广东东阳光药业有限公司 |
一种异构体的消旋方法
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
WO2016046679A1
(en)
*
|
2014-09-28 |
2016-03-31 |
Mohan M Alapati |
Compositions and methods for the treatment of diabetes and pre-diabetes
|
MX2017005186A
(es)
|
2014-10-20 |
2017-07-26 |
Neuralstem Inc |
Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
|
CN107405332A
(zh)
|
2015-01-06 |
2017-11-28 |
艾尼纳制药公司 |
治疗与s1p1受体有关的病症的方法
|
MX2017009004A
(es)
|
2015-01-08 |
2018-03-15 |
Lee Pharma Ltd |
Nuevo proceso para la preparacion del inhibidor de la enzima dipeptidil peptidasa-4 (dpp-4).
|
CZ27898U1
(cs)
|
2015-01-13 |
2015-03-02 |
Zentiva, K.S. |
Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
|
CZ27930U1
(cs)
|
2015-01-13 |
2015-03-10 |
Zentiva, K.S. |
Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
CN107426996B
(zh)
*
|
2015-04-15 |
2019-04-16 |
瓦伦特生物科学有限责任公司 |
(s)-2’-乙烯基脱落酸衍生物
|
KR101772898B1
(ko)
|
2015-06-11 |
2017-08-31 |
동방에프티엘(주) |
시타글립틴의 개선된 제조방법
|
KR101709127B1
(ko)
|
2015-06-16 |
2017-02-22 |
경동제약 주식회사 |
Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
|
CA3002551A1
(en)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
|
CN105017260B
(zh)
*
|
2015-07-30 |
2017-04-19 |
新发药业有限公司 |
一种西他列汀中间体三唑并吡嗪衍生物的制备方法
|
US11000521B2
(en)
|
2015-08-03 |
2021-05-11 |
Institut Pasteur |
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
|
KR20170036288A
(ko)
|
2015-09-24 |
2017-04-03 |
주식회사 종근당 |
시타글립틴의 신규염 및 이의 제조방법
|
WO2017064635A2
(en)
|
2015-10-14 |
2017-04-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
EP3159343B1
(en)
*
|
2015-10-22 |
2017-07-19 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Improved process for the preparation of triazole and salt thereof
|
US20190382363A1
(en)
|
2015-11-30 |
2019-12-19 |
Merck Sharp & Dohme Corp. |
Aryl sulfonamides as blt1 antagonists
|
US10450309B2
(en)
|
2015-11-30 |
2019-10-22 |
Merch Sharp & Dohme Corp. |
Aryl sulfonamides as BLT1 antagonists
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
WO2018034918A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
EP3496715B1
(en)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
CN106124667B
(zh)
*
|
2016-08-29 |
2018-07-31 |
上海应用技术学院 |
一种分离测定西格列汀有关物质的方法
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
MX2016016260A
(es)
|
2016-12-08 |
2018-06-07 |
Alparis Sa De Cv |
Nuevas formas solidas de sitagliptina.
|
JP6840853B2
(ja)
|
2016-12-09 |
2021-03-10 |
カディラ・ヘルスケア・リミテッド |
原発性胆汁性胆管炎の治療
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
US11197949B2
(en)
*
|
2017-01-19 |
2021-12-14 |
Medtronic Minimed, Inc. |
Medication infusion components and systems
|
US10047094B1
(en)
|
2017-02-10 |
2018-08-14 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Process for the preparation of triazole and salt thereof
|
CN110520124A
(zh)
|
2017-02-16 |
2019-11-29 |
艾尼纳制药公司 |
用于治疗原发性胆汁性胆管炎的化合物和方法
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのPPARγアゴニスト
|
US20180303837A1
(en)
|
2017-04-24 |
2018-10-25 |
Novartis Ag |
Therapeutic regimen
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
US11096890B2
(en)
|
2017-09-29 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
Chewable dosage forms containing sitagliptin and metformin
|
KR20190060235A
(ko)
|
2017-11-24 |
2019-06-03 |
제일약품주식회사 |
시타글립틴 캄실산염의 제조방법
|
TR201722603A2
(tr)
|
2017-12-28 |
2019-07-22 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
|
CN108586346B
(zh)
|
2018-05-10 |
2019-10-01 |
北京富盛嘉华医药科技有限公司 |
一种生物催化合成西他列汀及其中间体的方法
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
EP4045048A4
(en)
|
2019-10-14 |
2023-05-24 |
Santa Farma Ilaç Sanayi A.S. |
ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS
|
KR20210057603A
(ko)
|
2019-11-12 |
2021-05-21 |
제이투에이치바이오텍 (주) |
시타글립틴의 제조방법
|
TW202227417A
(zh)
|
2020-08-18 |
2022-07-16 |
美商默沙東藥廠 |
雙環庚烷吡咯啶之食慾素受體促效劑
|
KR102589305B1
(ko)
|
2021-04-22 |
2023-10-16 |
주식회사 메디켐코리아 |
시타글립틴 인산염의 개선된 제조방법
|
CN113979896A
(zh)
*
|
2021-11-18 |
2022-01-28 |
浙江永太手心医药科技有限公司 |
一种西格列汀杂质i及其制备方法
|
WO2023139276A1
(en)
|
2022-01-24 |
2023-07-27 |
Zaklady Farmaceutyczne Polpharma S.A. |
Process for preparing crystalline sitagliptin hydrochloride monohydrate
|
WO2024086263A1
(en)
|
2022-10-21 |
2024-04-25 |
Merck Sharp & Dohme Llc |
Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant
|
WO2024121301A1
(en)
|
2022-12-09 |
2024-06-13 |
Krka, D.D., Novo Mesto |
Process for the preparation of sitagliptin
|
EP4431087A1
(en)
|
2023-03-14 |
2024-09-18 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet of sitagliptin or a pharmaceutically acceptable salt thereof
|